In that regard, GAB2 deficiency could mimic, at least in part, the effects of the AML relevant multi-kinase inhibitors sorafenib and midostaurin, while more selective drugs such as quizartinib rather imitate FLT3-ITD deficiency [58]. The gene discussed is GAB2; the disease is acute myeloid leukemia.